Pasar al contenido principal

UNA APROXIMACION TRASLACIONAL A LA INTERPRETACION DE VARIANTES DE SECUENCIA EN PROTEINAS: INTEGRANDO IMPACTO MOLECULAR, REGULACION POR EL ENTORNO GENETICO Y COSTE CLINICO

PID2019-111217RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders

  • Gracia-Díaz, Carolina
  • Zhou, Yijing
  • Yang, Qian
  • Maroofian, Reza
  • España-Bonilla, Paula
  • Lee, Chul-Hwan
  • Zhang, Shuo
  • Padilla, Natàlia
  • Fueyo, Raquel
  • Waxman, Elisa A.
  • Lei, Sunyimeng
  • Otrimski, Garrett
  • Li, Dong
  • Sheppard, Sarah E.
  • Mark, Paul
  • Harr, Margaret H.
  • Hakonarson, Hakon
  • Rodan, Lance
  • Jackson, Adam
  • Vasudevan, Pradeep
  • Powel, Corrina
  • Mohammed, Shehla
  • Maddirevula, Sateesh
  • Alzaidan, Hamad
  • Faqeih, Eissa A.
  • Efthymiou, Stephanie
  • Turchetti, Valentina
  • Rahman, Fátima
  • Maqbool, Shazia
  • Salpietro, Vincenzo
  • Ibrahim, Shahnaz H.
  • di Rosa, Gabriella
  • Houlden, Henry
  • Alharbi, Maha Nasser
  • Al-Sannaa, Nouriya Abbas
  • Bauer, Peter
  • Zifarelli, Giovanni
  • Estaras, Conchi
  • Hurst, Anna C. E.
  • Thompson, Michelle L.
  • Chassevent, Anna
  • Smith-Hicks, Constance L.
  • Cruz, Xavier de la
  • Holtz, Alexander M.
  • Elloumi, Houda Zghal
  • Hajianpour, M. J.
  • Rieubland, Claudine
  • Braun, Dominique
  • Banka, Siddharth
  • French, Deborah L.
  • Heller, Elizabeth A.
  • Saade, Murielle
  • Song, Hongjun
  • Ming, Guo-Li
  • Alkuraya, Fowzan S.
  • Agrawal, Pankaj B.
  • Reinberg, Danny
  • Bhoj, Elizabeth J.
  • Martínez-Balbás, Marian
  • Akizu, Naiara
Genetic variants in chromatin regulators are frequently found in neurodevelopmental disorders, but their effect in disease etiology is rarely determined. Here, we uncover and functionally define pathogenic variants in the chromatin modifier EZH1 as the cause of dominant and recessive neurodevelopmental disorders in 19 individuals. EZH1 encodes one of the two alternative histone H3 lysine 27 methyltransferases of the PRC2 complex. Unlike the other PRC2 subunits, which are involved in cancers and developmental syndromes, the implication of EZH1 in human development and disease is largely unknown. Using cellular and biochemical studies, we demonstrate that recessive variants impair EZH1 expression causing loss of function effects, while dominant variants are missense mutations that affect evolutionarily conserved aminoacids, likely impacting EZH1 structure or function. Accordingly, we found increased methyltransferase activity leading to gain of function of two EZH1 missense variants. Furthermore, we show that EZH1 is necessary and sufficient for differentiation of neural progenitor cells in the developing chick embryo neural tube. Finally, using human pluripotent stem cell-derived neural cultures and forebrain organoids, we demonstrate that EZH1 variants perturb cortical neuron differentiation. Overall, our work reveals a critical role of EZH1 in neurogenesis regulation and provides molecular diagnosis for previously undefined neurodevelopmental disorders., This work was supported by the CHOP/UPENN IDDRC-New Program Development award, CHOP-Junior Faculty Pilot Program award, Margaret Q Landerbergen Foundation Award and NIH/NINDS R01NS119699, NIH/NICHD R21HD107592 (to N.A.), NIH/NINDS R35NS116843 (to H.S.), NIH/NINDS R35NS097370 and NIH/NIMH RF1MH123979 (to G.-l.M.)., BFU2015-69248-P and PGC2018-096082-B-I00 from the Spanish Ministry of Economy (to M.A.M.B.), Alabama Genomic Health Initiative F170303004 through University of Alabama at Birmingham (to A.C.H., M.T.), PID2019-111217RB-I00 Spanish Ministerio de Ciencia e Innovación (to X.D.L.C.), ID2019-110157RA-I00 (to M.S.), FPU Spanish Ministry of Education and Science predoctoral fellowship (to R.F.) and 2021 FISDU 00400 (to P.E-B.), NIHR Manchester Biomedical Research Centre NIHR203308 and Solve-RD which is supported by the European Union’s Horizon 2020 research and innovation program grant agreement No 779257 (to S.B.). This research was made possible through access to the data and findings generated by the 100KGP and the DDD. The 100KGP is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100KGP is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100KGP uses data provided by patients and collected by the National Health Service as part of their care and support. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. The views expressed in this publication are those of the author(s) and not necessarily those of Wellcome or the Department of Health. The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Ozkan, Selen
Endofenotip; Prediccions de patogenicitat; Predictor específic de proteïna, Endofenotipo; Predicciones de patogenicidad; Predictor específico de proteína, Endophenotype; Pathogenicity predictions; Protein-specific predictor, The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements., This research was funded by the EU European Regional Development Fund (ERDF) through the Program Interreg V-A Spain-France-Andorra (POCTEFA), grant number EFA086/15-PIREPRED, by the Spanish Ministerio de Ciencia e Innovación, grant number PID2019-111217RB-I00, and by the Spanish Ministerio de Economía y Competitividad, grant number SAF2016-80255-R.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The histone demethylase PHF8 regulates astrocyte differentiation and function

  • Padilla Sirera, Natalia
  • Gabrielli, Martina
  • Navarro, Claudia
  • Lombardi, Marta
  • Vicioso Mantis, Marta
  • De la Cruz Montserrat, Fco. Xavier
  • Iacobucci, Simona
Astrocyte differentiation; Chromatin transcription; Synapse, Diferenciación de astrocitos; Transcripción de la cromatina; Sinapsis, Diferenciació d'astròcits; Transcripció de la cromatina; Sinapsi, Epigenetic factors have been shown to play a crucial role in X-linked intellectual disability (XLID). Here, we investigate the contribution of the XLID-associated histone demethylase PHF8 to astrocyte differentiation and function. Using genome-wide analyses and biochemical assays in mouse astrocytic cultures, we reveal a regulatory crosstalk between PHF8 and the Notch signaling pathway that balances the expression of the master astrocytic gene Nfia. Moreover, PHF8 regulates key synaptic genes in astrocytes by maintaining low levels of H4K20me3. Accordingly, astrocytic-PHF8 depletion has a striking effect on neuronal synapse formation and maturation in vitro. These data reveal that PHF8 is crucial in astrocyte development to maintain chromatin homeostasis and limit heterochromatin formation at synaptogenic genes. Our studies provide insights into the involvement of epigenetics in intellectual disability., This study was supported by grants from the Spanish Ministry of Economy (Ministerio de Economía, Industria y Competitividad, Gobierno de España; BFU2015-69248-P and PGC2018-096082-B-I00 to M.A.M.-B.) and Ministerio de Ciencia e Innovación (PID2019-111217RB-I00 to X.C) and a Travelling Fellowship from Boehringer Ingelheim to S.I. Open access funding provided by Consejo Superior de Investigaciones Científicas. Deposited in PMC for immediate release.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Choosing Variant Interpretation Tools for Clinical Applications: Context Matters

  • Aguirre, Josu
  • Padilla Sirera, Natàlia
  • Ozkan, Selen
  • Riera, Casandra
  • Feliubadaló, Lidia
  • De la Cruz Montserrat, Fco. Xavier
Clinical variant interpretation; Healthcare costs; Pathogenicity prediction, Interpretación de variantes clínicas; Costes sanitarios; Predicción de patogenicidad, Interpretació de variants clíniques; Despeses sanitàries; Predicció de patogenicitat, Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers., This work was supported by research grants SAF2016-80255-R from the Spanish Ministerio de Economía y Competitividad (MINECO), PID2019-111217RB-I00 and TED2021-130342B-I00 from the Spanish Ministerio de Ciencia e Innovación, and by the European Regional Development Fund (ERDF) through the Interreg program POCTEFA (Pirepred, EFA086/15).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mechanism of KMT5B haploinsufficiency in neurodevelopment in humans and mice

  • Sheppard, Sarah E.
  • Bryant, Laura
  • Wickramasekara, Rochelle
  • Vaccaro, Courtney
  • Robertson, Brynn
  • Hallgren, Jodi
  • Padilla Sirera, Natalia
  • Cueto Gonzalez, Anna Maria
  • De la Cruz Montserrat, Fco. Xavier
KMT5B gene; Neurodevelopment; Mice, Gen KMT5B; Neurodesenvolupament; Ratolins, Gen KMT5B; Neurodesarrollo; Ratones, Pathogenic variants in KMT5B, a lysine methyltransferase, are associated with global developmental delay, macrocephaly, autism, and congenital anomalies (OMIM# 617788). Given the relatively recent discovery of this disorder, it has not been fully characterized. Deep phenotyping of the largest (n = 43) patient cohort to date identified that hypotonia and congenital heart defects are prominent features that were previously not associated with this syndrome. Both missense variants and putative loss-of-function variants resulted in slow growth in patient-derived cell lines. KMT5B homozygous knockout mice were smaller in size than their wild-type littermates but did not have significantly smaller brains, suggesting relative macrocephaly, also noted as a prominent clinical feature. RNA sequencing of patient lymphoblasts and Kmt5b haploinsufficient mouse brains identified differentially expressed pathways associated with nervous system development and function including axon guidance signaling. Overall, we identified additional pathogenic variants and clinical features in KMT5B-related neurodevelopmental disorder and provide insights into the molecular mechanisms of the disorder using multiple model systems., This work was supported by LB692 Nebraska Tobacco Settlement Biomedical Research Development Program (to H.A.F.S.); The Simons Foundation Autism Research Initiative–Bridge to Independence Award SFARI 381192 (to H.A.F.S.); The A*STAR, Singapore, IAF-PP Program H17/01/a0/004 (to C.Y.L.); The Wong Boon Hock Society research program Yong Loo Lin School of Medicine (to Z.X.C.); NIH training grant 2T32GM008638-25 (L.B.); The Intramural Research Program of the National Human Genome Research Institute (to W.G.); The National Center for Advancing Translational Sciences of the NIH award number TL1TR001880 (to S.E.S.); The Eunice Kennedy Shriver National Institute of Child Health and Human Development award number HD009003-01 (to S.E.S.); Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania (to S.E.S.); and Swiss National Science Foundation (SNSF) grant 320020_179547 and funds from the University of Zurich Research Priority Programs (URPP) AdaBD: Adaptive Brain Circuits in Developments (to A.Rau.). F.J.K. was funded by the Deutsche Forschungsgemeinschaft grant number FOR 2488. In silico modeling was supported by the Spanish Ministerio de Ciencia e Innovación grant number PID2019-111217RB-I00 (to X.d.l.C.). This study used data from the DDD study. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003). This study makes use of DECIPHER (www.deciphergenomics.org), which is funded by Wellcome (grant number 223718/Z/21/Z). See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

QAFI: a novel method for quantitative estimation of missense variant impact using protein-specific predictors and ensemble learning

  • Ozkan, Selen
  • Padilla Sirera, Natàlia
  • De la Cruz Montserrat, Fco. Xavier
Seqüenciació de nova generació; Diagnòstic genètic; Medicina de precisió, Next-generation sequencing; Genetic diagnostic; Precision medicine, Secuenciación de nueva generación; Diagnóstico genético; Medicina de precisión, Next-generation sequencing (NGS) has revolutionized genetic diagnostics, yet its application in precision medicine remains incomplete, despite significant advances in computational tools for variant annotation. Many variants remain unannotated, and existing tools often fail to accurately predict the range of impacts that variants have on protein function. This limitation restricts their utility in relevant applications such as predicting disease severity and onset age. In response to these challenges, a new generation of computational models is emerging, aimed at producing quantitative predictions of genetic variant impacts. However, the field is still in its early stages, and several issues need to be addressed, including improved performance and better interpretability. This study introduces QAFI, a novel methodology that integrates protein-specific regression models within an ensemble learning framework, utilizing conservation-based and structure-related features derived from AlphaFold models. Our findings indicate that QAFI significantly enhances the accuracy of quantitative predictions across various proteins. The approach has been rigorously validated through its application in the CAGI6 contest, focusing on ARSA protein variants, and further tested on a comprehensive set of clinically labeled variants, demonstrating its generalizability and robust predictive power. The straightforward nature of our models may also contribute to better interpretability of the results., This work was supported by the Ministerio de Ciencia e Innovación de España through grants PID2019-111217RB-I00 and PID2022-142753OB-I00, both co-funded by the European Regional Development Fund (FEDER); and by grant TED2021-130342B-I00, funded by the Next Generation EU funds.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2, In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • de la Cruz, Xavier|||0000-0002-9738-8472
The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CAGI, the Critical Assessment of Genome Interpretation, establishes progress and prospects for computational genetic variant interpretation methods

  • Jain, Shantanu
  • Bakolitsa, Constantina|||0000-0002-6980-9831
  • Brenner, Steven E.
  • Radivojac, Predrag
  • Moult, John
  • Repo, Susanna
  • Hoskins, Roger A.
  • Andreoletti, Gaia
  • Barsky, Daniel
  • Chellapan, Ajithavalli
  • Chu, Hoyin
  • Dabbiru, Navya
  • Kollipara, Naveen K.
  • Ly, Melissa
  • Neumann, Andrew J.
  • Pal, Lipika R.
  • Odell, Eric
  • Pandey, Gaurav
  • Peters-Petrulewicz, Robin C.
  • Srinivasan, Rajgopal
  • Yee, Stephen F.
  • Yeleswarapu, Sri Jyothsna
  • Zuhl, Maya
  • Adebali, Ogun
  • Patra, Ayoti
  • Beer, Michael A.
  • Hosur, Raghavendra
  • Peng, Jian
  • Bernard, Brady M.
  • Berry, Michael
  • Dong, Shengcheng
  • Boyle, Alan P.
  • Adhikari, Aashish
  • Chen, Jingqi
  • Hu, Zhiqiang
  • Wang, Robert
  • Wang, Yaqiong
  • Miller, Maximilian
  • Wang, Yanran
  • Bromberg, Yana
  • Turina, Paola
  • Capriotti, Emidio|||0000-0002-2323-0963
  • Han, James J.
  • Ozturk, Kivilcim
  • Carter, Hannah
  • Babbi, Giulia|||0000-0002-9816-4737
  • Bovo, Samuele
  • Di Lena, Pietro
  • Martelli, Pier Luigi|||0000-0002-0274-5669
  • Savojardo, Castrense
  • Casadio, Rita
  • Cline, Melissa S.
  • De Baets, Greet
  • Bonache, Sandra|||0000-0002-7395-8143
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Fernández, Alejandro
  • Montalban, Gemma|||0000-0002-6958-4759
  • Ootes, Lars
  • Özkan, Selen|||0000-0002-7398-1351
  • Padilla Sirera, Natàlia|||0000-0002-7872-2279
  • Riera, Casandra
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Diekhans, Mark|||0000-0002-0430-0989
  • Huwe, Peter J.
  • Wei, Qiong
  • Xu, Qifang
  • Dunbrack, Roland L.
  • Gotea, Valer|||0000-0001-7857-3309
  • Elnitski, Laura
  • Margolin, Gennady
  • Fariselli, Piero
  • Kulakovskiy, Ivan V.
  • Makeev, V.J.|||0000-0001-9405-9748
  • Penzar, Dmitry D.
  • Vorontsov, Ilya E.
  • Favorov, A.V.
  • Forman, Julia R.
  • Hasenahuer, Marcia
  • Fornasari, Maria S.
  • Parisi, Gustavo|||0000-0001-7444-1624
  • Avsec, Ziga
  • Çelik, Muhammed H.
  • Nguyen, Thi Yen Duong
  • Gagneur, Julien|||0000-0002-8924-8365
  • Shi, Fang-Yuan
  • Edwards, Matthew D.|||0000-0002-3573-0025
  • Guo, Yuchun
  • Tian, Kevin
  • Zeng, Haoyang
  • Gifford, David K.
  • Göke, Jonathan
  • Zaucha, Jan|||0000-0003-3289-4590
  • Gough, Julian
  • Ritchie, Graham R.S.
  • Frankish, Adam|||0000-0002-4333-628X
  • Mudge, Jonathan M.
  • Harrow, Jennifer
  • Young, Erin L.
  • Yu, Yao|||0000-0002-2727-1746
  • Huff, Chad D.
  • Murakami, Katsuhiko
  • Nagai, Yoko
  • Imanishi, Tadashi
  • Mungall, Christopher J.
  • Jacobsen, Julius O.B.
  • Kim, Dongsup
  • Jeong, Chan-Seok
  • Jones, David T.
  • Li, Mulin Jun
  • Guthrie, Violeta Beleva
  • Bhattacharya, Rohit
  • Chen, Yun-Ching
  • Douville, Christopher
  • Fan, Jean
  • Kim, Dewey
  • Masica, David
  • Niknafs, Noushin
  • Sengupta, Sohini
  • Tokheim, Collin
  • Turner, Tychele N.
  • Yeo, Hui Ting Grace|||0000-0002-8920-8208
  • Karchin, Rachel
  • Shin, Sunyoung
  • Welch, Rene
  • Keles, Sunduz
  • Li, Yue
  • Kellis, Manolis
  • Corbi-Verge, Carles
  • Strokach, Alexey V.
  • Kim, Philip M.
  • Klein, Teri E.|||0000-0001-5527-6475
  • Mohan, Rahul
  • Sinnott-Armstrong, Nicholas A.
  • Wainberg, Michael
  • Kundaje, Anshul|||0000-0003-3084-2287
  • Gonzaludo, Nina
  • Mak, A.C.Y.
  • Chhibber, Aparna
  • Lam, Hugo Y.K.
  • Dahary, Dvir|||0000-0002-0974-8037
  • Fishilevich, S.
  • Lancet, Doron
  • Lee, Insuk
  • Bachman, Benjamin
  • Katsonis, Panagiotis
  • Lua, Rhonald C.
  • Wilson, Stephen J.
  • Lichtarge, Olivier
  • Bhat, Rajendra R.
  • Sundaram, Laksshman
  • Viswanath, Vivek
  • Bellazzi, Riccardo
  • Nicora, Nicora
  • Rizzo, Ettore
  • Limongelli, Ivan
  • Mezlini, Aziz M.
  • Chang, Ray
  • Kim, Serra
  • Lai, Carmen
  • O'Connor, Robert
  • Topper, Scott
  • van den Akker, Jeroen
  • Zhou, Alicia Y.
  • Zimmer, Anjali D.
  • Mishne, Gilad
  • Bergquist, Timothy R.
  • Breese, Marcus R.
  • Guerrero, Rafael F.|||0000-0002-8451-3609
  • Jiang, Yuxiang
  • Kiga, Nikki
  • Li, Biao
  • Mort, Matthew
  • Pagel, Kymberleigh A.
  • Pejaver, Vikas
  • Stamboulian, Moses H.
  • Thusberg, Janita
  • Mooney, Sean D.
  • Teerakulkittipong, Nuttinee|||0000-0002-2172-9277
  • Cao, Chen
  • Kundu, Kunal
  • Yin, Yizhou
  • Yu, Chen-Hsin
  • Kleyman, Michael
  • Lin, Chiao-Feng
  • Stackpole, Mary
  • Mount, Stephen M.
  • Eraslan, Gökcen
  • Mueller, Nikola S.
  • Naito, Tatsuhiko
  • Rao, Aliz R.
  • Azaria, Johnathan R.
  • Brodie, Aharon
  • Ofran, Yanay
  • Garg, Aditi
  • Pal, Debnath
  • Hawkins-Hooker, Alex
  • Kenlay, Henry
  • Reid, John
  • Mucaki, Eliseos J.
  • Rogan, Peter K.|||0000-0003-2070-5254
  • Schwarz, Jana M.
  • Searls, David B.
  • Lee, Gyu R.
  • Seok, Chaok
  • Krämer, Andreas
  • Shah, Sohela
  • Huang, ChengLai V.
  • Kirsch, Jack F.
  • Shatsky, Maxim
  • Cao, Yue
  • Chen, Haoran
  • Karimi, Mostafa
  • Moronfoye, Oluwaseyi
  • Sun, Yuanfei
  • Shen, Yang
  • Shigeta, Ron
  • Ford, Colby T.
  • Nodzak, Conor
  • Uppal, Aneeta
  • Shi, Xinghua
  • Joseph, Thomas
  • Kotte, Sujatha
  • Rana, Sadhna
  • Rao, Aditya
  • Saipradeep, Vangala G.
  • Sivadasan, Naveen
  • Sunderam, Uma
  • Stanke, Mario
  • Su, Andrew
  • Adzhubey, Ivan
  • Jordan, Daniel M.
  • Sunyaev, Shamil|||0000-0001-5715-5677
  • Rousseau, Frederic
  • Schymkowitz, Joost
  • Van Durme, Joost
  • Tavtigian, Sean V.
  • Carraro, Marco
  • Giollo, Manuel
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Adato, Orit|||0000-0002-2135-8947
  • Carmel, Liran|||0000-0003-0225-8550
  • Cohen, Noa E.|||0000-0002-4638-5407
  • Fenesh, Tzila
  • Holtzer, Tamar
  • Juven-Gershon, Tamar|||0000-0003-2607-5476
  • Unger, Ron
  • Niroula, Abhishek
  • Olatubosun, Ayodeji
  • Väliaho, Jouni
  • Yang, Yang
  • Vihinen, Mauno
  • Wahl, Mary E.
  • Chang, Billy
  • Chong, Ka C.
  • Hu, Inchi
  • Sun, Rui
  • Wu, William Ka Ke|||0000-0002-5662-5240
  • Xia, Xiaoxuan
  • Zee, Benny C.
  • Wang, Maggie Haitian|||0000-0003-1223-4595
  • Wang, Meng
  • Wu, Chunlei
  • Lu, Yutong
  • Chen, Ken
  • Yang, Yuedong
  • Yates, Christopher M.
  • Kreimer, Anat
  • Yan, Zhongxia
  • Yosef, Nir|||0000-0001-9004-1225
  • Zhao, Huying
  • Wei, Zhipeng
  • Yao, Zhaomin
  • Fengfeng, Zhou
  • Folkman, Lukas|||0000-0002-5811-8875
  • Zhou, Yaoqi
  • Daneshjou, Roxana|||0000-0001-7988-9356
  • Altman, Russ B.
  • Inoue, Fumitaka
  • Ahituv, Nadav
  • Arkin, Adam P.
  • Lovisa, Federica
  • Bonvini, Paolo
  • Bowdin, Sarah
  • Gianni, Stefano
  • Mantuano, Elide
  • Minicozzi, Velia
  • Novak, Leonore
  • Pasquo, Alessandra
  • Pastore, Annalisa|||0000-0002-3047-654X
  • Petrosino, Maria
  • Puglisi, Rita
  • Toto, Angelo
  • Veneziano, Liana
  • Chiaraluce, Roberta
  • Ball, Mad P.
  • Bobe, Jason R.
  • Church, George M.
  • Consalvi, Valerio
  • Cooper, David N.|||0000-0002-8943-8484
  • Buckley, Bethany A.
  • Sheridan, Molly B.
  • Cutting, Garry R.
  • Scaini, Maria Chiara|||0000-0002-9583-3034
  • Cygan, Kamil J.
  • Fredericks, Alger M.
  • Glidden, David T.
  • Neil, Christopher
  • Rhine, Christy L.|||0000-0002-5758-5543
  • Fairbrother, William G.
  • Alontaga, Aileen Y.
  • Fenton, Aron W.
  • Matreyek, Kenneth|||0000-0001-9149-551X
  • Starita, Lea M.
  • Fowler, Douglas M.
  • Löscher, Britt-Sabina
  • Franke, Andre|||0000-0003-1530-5811
  • Adamson, Scott I.
  • Graveley, Brenton R.
  • Gray, Joe W.
  • Malloy, Mary J.
  • Kane, John P.
  • Kousi, Maria
  • Katsanis, Nicholas
  • Schubach, Max
  • Kircher, Martin
  • Mak, Angel C.Y.
  • Tang, Paul L.F.
  • Kwok, Pui-Yan
  • Lathrop, Richard H.
  • Clark, Wyatt T.
  • Yu, Guoying K.
  • LeBowitz, Jonathan H.
  • Benedicenti, Francesco|||0000-0002-9458-0688
  • Bettella, Elisa
  • Bigoni, Stefania
  • Cesca, Federica
  • Mammi, Isabella
  • Marino-Buslje, Cristina|||0000-0002-6564-1920
  • Milani, Donatella
  • Peron, Angela|||0000-0002-1769-6548
  • Polli, Roberta
  • Sartori, Stefano
  • Stanzial, Franco
  • Toldo, Irene
  • Turolla, Licia
  • Aspromonte, Maria Cristina|||0000-0002-4937-6952
  • Bellini, Mariagrazia
  • Leonardi, Emanuela|||0000-0001-8486-8461
  • Liu, Xiaoming|||0000-0001-8285-5528
  • Marshall, Christian
  • McCombie, W. Richard
  • Elefanti, Lisa
  • Menin, Chiara
  • Meyn, M. Stephen
  • Murgia, Alessandra
  • Nadeau, Kari C.Y.
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Pirooznia, Mehdi|||0000-0002-4210-6458
  • Potash, James B.
  • Dimster-Denk, Dago F.
  • Rine, Jasper D.
  • Sanford, Jeremy R.
  • Snyder, Michael|||0000-0003-0784-7987
  • Cote, Atina G.
  • Sun, Song
  • Verby, Marta W.
  • Weile, Jochen
  • Roth, Frederick P.
  • Tewhey, Ryan
  • Sabeti, Pardis C.
  • Campagna, Joan
  • Refaat, Marwan M.
  • Wojciak, Julianne
  • Grubb, Soren
  • Schmitt, Nicole
  • Shendure, Jay
  • Spurdle, Amanda B.
  • Stavropoulos, Dimitri J.
  • Walton, Nephi A.
  • Zandi, Peter P.
  • Ziv, Elad
  • Burke, Wylie
  • Chen, Flavia
  • Carr, Lawrence R.
  • Martinez, Selena
  • Paik, Jodi
  • Harris-Wai, Julie
  • Yarborough, Mark|||0000-0001-8188-4968
  • Fullerton, Stephanie M.
  • Koenig, Barbara A.
  • McInnes, Gregory
  • Shigaki, Dustin
  • Chandonia, John-Marc
  • Furutsuki, Mabel
  • Kasak, Laura|||0000-0003-4182-2396
  • Yu, Changhua
  • Chen, Rui
  • Friedberg, Iddo
  • Getz, Gad A.
  • Cong, Qian
  • Kinch, Lisa N.
  • Zhang, Jing
  • Grishin, Nick V.
  • Voskanian, Alin
  • Kann, Maricel G.
  • Tran, Elizabeth
  • Ioannidis, Nilah M.
  • Hunter, Jesse M.
  • Udani, Rupa
  • Cai, Binghuang
  • Morgan, Alexander A.
  • Sokolov, Artem
  • Stuart, Joshua M.|||0000-0002-2171-565X
  • Minervini, Giovanni|||0000-0001-7013-5785
  • Monzon, Alexander M.
  • Batzoglou, Serafim
  • Butte, Atul J.
  • Greenblatt, Marc S.
  • Hart, Reece K.
  • Hernandez, Ryan
  • Hubbard, Tim J.P.
  • Kahn, Scott
  • O'Donnell-Luria, Anne|||0000-0001-6418-9592
  • Ng, Pauline C.
  • Shon, John
  • Veltman, Joris
  • Zook, Justin M.|||0000-0003-2309-8402
Background: The Critical Assessment of Genome Interpretation (CAGI) aims to advance the state-of-the-art for computational prediction of genetic variant impact, particularly where relevant to disease. The five complete editions of the CAGI community experiment comprised 50 challenges, in which participants made blind predictions of phenotypes from genetic data, and these were evaluated by independent assessors. Results: Performance was particularly strong for clinical pathogenic variants, including some difficult-to-diagnose cases, and extends to interpretation of cancer-related variants. Missense variant interpretation methods were able to estimate biochemical effects with increasing accuracy. Assessment of methods for regulatory variants and complex trait disease risk was less definitive and indicates performance potentially suitable for auxiliary use in the clinic. Conclusions: Results show that while current methods are imperfect, they have major utility for research and clinical applications. Emerging methods and increasingly large, robust datasets for training and assessment promise further progress ahead.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The histone demethylase PHF8 regulates astrocyte differentiation and function

  • Padilla Sirera, Natalia
  • Gabrielli, Martina
  • Navarro, Claudia
  • Lombardi, Marta
  • Vicioso Mantis, Marta
  • De la Cruz Montserrat, Fco. Xavier
  • Iacobucci, Simona
Astrocyte differentiation; Chromatin transcription; Synapse, Diferenciación de astrocitos; Transcripción de la cromatina; Sinapsis, Diferenciació d'astròcits; Transcripció de la cromatina; Sinapsi, Epigenetic factors have been shown to play a crucial role in X-linked intellectual disability (XLID). Here, we investigate the contribution of the XLID-associated histone demethylase PHF8 to astrocyte differentiation and function. Using genome-wide analyses and biochemical assays in mouse astrocytic cultures, we reveal a regulatory crosstalk between PHF8 and the Notch signaling pathway that balances the expression of the master astrocytic gene Nfia. Moreover, PHF8 regulates key synaptic genes in astrocytes by maintaining low levels of H4K20me3. Accordingly, astrocytic-PHF8 depletion has a striking effect on neuronal synapse formation and maturation in vitro. These data reveal that PHF8 is crucial in astrocyte development to maintain chromatin homeostasis and limit heterochromatin formation at synaptogenic genes. Our studies provide insights into the involvement of epigenetics in intellectual disability., This study was supported by grants from the Spanish Ministry of Economy (Ministerio de Economía, Industria y Competitividad, Gobierno de España; BFU2015-69248-P and PGC2018-096082-B-I00 to M.A.M.-B.) and Ministerio de Ciencia e Innovación (PID2019-111217RB-I00 to X.C) and a Travelling Fellowship from Boehringer Ingelheim to S.I. Open access funding provided by Consejo Superior de Investigaciones Científicas. Deposited in PMC for immediate release.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants

  • Padilla Sirera, Natalia
  • De la Cruz Montserrat, Fco. Xavier
  • Ozkan, Selen
Endofenotip; Prediccions de patogenicitat; Predictor específic de proteïna, Endofenotipo; Predicciones de patogenicidad; Predictor específico de proteína, Endophenotype; Pathogenicity predictions; Protein-specific predictor, The present limitations in the pathogenicity prediction of BRCA1 and BRCA2 (BRCA1/2) missense variants constitute an important problem with negative consequences for the diagnosis of hereditary breast and ovarian cancer. However, it has been proposed that the use of endophenotype predictions, i.e., computational estimates of the outcomes of functional assays, can be a good option to address this bottleneck. The application of this idea to the BRCA1/2 variants in the CAGI 5-ENIGMA international challenge has shown promising results. Here, we developed this approach, exploring the predictive performances of the regression models applied to the BRCA1/2 variants for which the values of the homology-directed DNA repair and saturation genome editing assays are available. Our results first showed that we can generate endophenotype estimates using a few molecular-level properties. Second, we show that the accuracy of these estimates is enough to obtain pathogenicity predictions comparable to those of many standard tools. Third, endophenotype-based predictions are complementary to, but do not outperform, those of a Random Forest model trained using variant pathogenicity annotations instead of endophenotype values. In summary, our results confirmed the usefulness of the endophenotype approach for the pathogenicity prediction of the BRCA1/2 missense variants, suggesting different options for future improvements., This research was funded by the EU European Regional Development Fund (ERDF) through the Program Interreg V-A Spain-France-Andorra (POCTEFA), grant number EFA086/15-PIREPRED, by the Spanish Ministerio de Ciencia e Innovación, grant number PID2019-111217RB-I00, and by the Spanish Ministerio de Economía y Competitividad, grant number SAF2016-80255-R.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Mechanism of KMT5B haploinsufficiency in neurodevelopment in humans and mice

  • Sheppard, Sarah E.
  • Bryant, Laura
  • Wickramasekara, Rochelle
  • Vaccaro, Courtney
  • Robertson, Brynn
  • Hallgren, Jodi
  • Padilla Sirera, Natalia
  • Cueto Gonzalez, Anna Maria
  • De la Cruz Montserrat, Fco. Xavier
KMT5B gene; Neurodevelopment; Mice, Gen KMT5B; Neurodesenvolupament; Ratolins, Gen KMT5B; Neurodesarrollo; Ratones, Pathogenic variants in KMT5B, a lysine methyltransferase, are associated with global developmental delay, macrocephaly, autism, and congenital anomalies (OMIM# 617788). Given the relatively recent discovery of this disorder, it has not been fully characterized. Deep phenotyping of the largest (n = 43) patient cohort to date identified that hypotonia and congenital heart defects are prominent features that were previously not associated with this syndrome. Both missense variants and putative loss-of-function variants resulted in slow growth in patient-derived cell lines. KMT5B homozygous knockout mice were smaller in size than their wild-type littermates but did not have significantly smaller brains, suggesting relative macrocephaly, also noted as a prominent clinical feature. RNA sequencing of patient lymphoblasts and Kmt5b haploinsufficient mouse brains identified differentially expressed pathways associated with nervous system development and function including axon guidance signaling. Overall, we identified additional pathogenic variants and clinical features in KMT5B-related neurodevelopmental disorder and provide insights into the molecular mechanisms of the disorder using multiple model systems., This work was supported by LB692 Nebraska Tobacco Settlement Biomedical Research Development Program (to H.A.F.S.); The Simons Foundation Autism Research Initiative–Bridge to Independence Award SFARI 381192 (to H.A.F.S.); The A*STAR, Singapore, IAF-PP Program H17/01/a0/004 (to C.Y.L.); The Wong Boon Hock Society research program Yong Loo Lin School of Medicine (to Z.X.C.); NIH training grant 2T32GM008638-25 (L.B.); The Intramural Research Program of the National Human Genome Research Institute (to W.G.); The National Center for Advancing Translational Sciences of the NIH award number TL1TR001880 (to S.E.S.); The Eunice Kennedy Shriver National Institute of Child Health and Human Development award number HD009003-01 (to S.E.S.); Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania (to S.E.S.); and Swiss National Science Foundation (SNSF) grant 320020_179547 and funds from the University of Zurich Research Priority Programs (URPP) AdaBD: Adaptive Brain Circuits in Developments (to A.Rau.). F.J.K. was funded by the Deutsche Forschungsgemeinschaft grant number FOR 2488. In silico modeling was supported by the Spanish Ministerio de Ciencia e Innovación grant number PID2019-111217RB-I00 (to X.d.l.C.). This study used data from the DDD study. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003). This study makes use of DECIPHER (www.deciphergenomics.org), which is funded by Wellcome (grant number 223718/Z/21/Z). See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

QAFI: a novel method for quantitative estimation of missense variant impact using protein-specific predictors and ensemble learning

  • Ozkan, Selen
  • Padilla Sirera, Natàlia
  • De la Cruz Montserrat, Fco. Xavier
Seqüenciació de nova generació; Diagnòstic genètic; Medicina de precisió, Next-generation sequencing; Genetic diagnostic; Precision medicine, Secuenciación de nueva generación; Diagnóstico genético; Medicina de precisión, Next-generation sequencing (NGS) has revolutionized genetic diagnostics, yet its application in precision medicine remains incomplete, despite significant advances in computational tools for variant annotation. Many variants remain unannotated, and existing tools often fail to accurately predict the range of impacts that variants have on protein function. This limitation restricts their utility in relevant applications such as predicting disease severity and onset age. In response to these challenges, a new generation of computational models is emerging, aimed at producing quantitative predictions of genetic variant impacts. However, the field is still in its early stages, and several issues need to be addressed, including improved performance and better interpretability. This study introduces QAFI, a novel methodology that integrates protein-specific regression models within an ensemble learning framework, utilizing conservation-based and structure-related features derived from AlphaFold models. Our findings indicate that QAFI significantly enhances the accuracy of quantitative predictions across various proteins. The approach has been rigorously validated through its application in the CAGI6 contest, focusing on ARSA protein variants, and further tested on a comprehensive set of clinically labeled variants, demonstrating its generalizability and robust predictive power. The straightforward nature of our models may also contribute to better interpretability of the results., This work was supported by the Ministerio de Ciencia e Innovación de España through grants PID2019-111217RB-I00 and PID2022-142753OB-I00, both co-funded by the European Regional Development Fund (FEDER); and by grant TED2021-130342B-I00, funded by the Next Generation EU funds.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Choosing Variant Interpretation Tools for Clinical Applications: Context Matters

  • Aguirre, Josu
  • Padilla Sirera, Natàlia
  • Ozkan, Selen
  • Riera, Casandra
  • Feliubadaló, Lidia
  • De la Cruz Montserrat, Fco. Xavier
Clinical variant interpretation; Healthcare costs; Pathogenicity prediction, Interpretación de variantes clínicas; Costes sanitarios; Predicción de patogenicidad, Interpretació de variants clíniques; Despeses sanitàries; Predicció de patogenicitat, Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers., This work was supported by research grants SAF2016-80255-R from the Spanish Ministerio de Economía y Competitividad (MINECO), PID2019-111217RB-I00 and TED2021-130342B-I00 from the Spanish Ministerio de Ciencia e Innovación, and by the European Regional Development Fund (ERDF) through the Interreg program POCTEFA (Pirepred, EFA086/15).